RxDoctor Payments Data

Rebecca Curtiss, MD

Internal Medicine · Mobile, ALNPI 1346254356

Payments from drug & device makers

$1,459in general payments, 2019–2025

Across 84 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$257
  • AbbVie$212
  • Daiichi Sankyo Inc.$166
  • AstraZeneca$159
  • Lilly USA, LLC$128
  • Bayer$86
  • plus $451 from 15 others

What the payments were for

  • Food & beverage$1,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,459 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$92,687
Medicare patients
208
Services billed
3,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$96,513
RybelsusSemaglutide36$49,601
MounjaroTirzepatide41$45,637
EliquisApixaban52$40,403
LinzessLinaclotide21$12,474
MyrbetriqMirabegron25$11,990
Breo ElliptaFluticasone/Vilanterol19$11,894
XareltoRivaroxaban11$11,503
VyvanseLisdexamfetamine Dimesylate19$7,158
Levothyroxine Sodium592$6,557
Omeprazole308$5,764
Famotidine237$5,547
Atorvastatin Calcium435$5,255
Losartan Potassium414$4,981
Venlafaxine Hcl ErVenlafaxine Hcl136$4,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$257$146,115103 claims
Lilly USA, LLCMounjaro$128$45,63741 claims
PfizerEliquis$70$40,40352 claims
AbbVieLinzess, Synthroid$212$14,92683 claims
GSKBreo Ellipta$30$11,89419 claims
Johnson & JohnsonXarelto$33$11,50311 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$15$7,15819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →